Search Within

Matthew David Hellmann

Formats
  1. Meeting Abstract (210)
  2. Journal Article (187)
  3. Review (5)
  4. Editorial (4)
  5. Research Letter (3)
  6. Guidelines (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (412)
  2. Solid Tumor Oncology Division (412)
  3. Thoracic Oncology (412)
  4. GSK Faculty (140)
  5. Department of Pathology and Laboratory Medicine (112)
  6. Weinberg Fellows (103)

More Groups

People
  1. Hira Rizvi (97)
  2. Mark Kris (71)
  3. Jamie Chaft (68)
  4. Charles Rudin (67)
  5. Jedd Wolchok (53)
  6. Gregory Riely (49)

More People

Years
  1. 2025 (2)
  2. 2024 (7)
  3. 2023 (14)
  4. 2022 (34)
  5. 2021 (40)
  6. 2020 (55)

More Years

Publications
  1. Journal of Clinical Oncology (91)
  2. Journal of Thoracic Oncology (58)
  3. Annals of Oncology (49)
  4. Journal for ImmunoTherapy of Cancer (30)
  5. Cancer Research (24)
  6. Clinical Cancer Research (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (96)
  2. Elsevier Inc. (75)
  3. American Association for Cancer Research (57)
  4. Oxford University Press (53)
  5. Biomed Central Ltd (30)
  6. Nature Publishing Group (21)

More Publishers

Results (412)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Peripheral T cell repertoire evolution in resectable NSCLC treated with neoadjuvant PD-1 blockade
    Meeting Abstract

    Zhang, J.; Ji, Z.; Caushi, J.; El Asmar, M.; Anagnostou, V.; Cottrell, T.; Chan, H. Y.; Guo, H.; Merghoub, T.; Chaft, J.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • STK11/LKB1 genomic alterations are associated with inferior clinical outcomes with chemo-immunotherapy in non-squamous NSCLC
    Meeting Abstract

    Skoulidis, F.; Arbour, K.; Hellmann, M.; Patil, P.; Marmarelis, M.; Owen, D.; Awad, M.; Murray, J.; Levy, B.; Hellyer, J.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Early change of dNLR is correlated with outcomes in advanced NSCLC patients treated with immunotherapy
    Meeting Abstract

    Mezquita, L.; Preeshagul, I.; Auclin, E.; Saravia, D.; Hendriks, L.; Rizvi, H.; Planchard, D.; Park, W.; Nadal, E.; Ruffinelli, J. C.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Multifactorial model to predict response to PD-(L)1 blockade in patients with high PD-L1 metastatic non-small cell lung cancer
    Meeting Abstract

    Arbour, K.; Oprescu, M.; Hakim, J.; Rizvi, H.; Leiserson, M.; Ginsburg, M.; Plodkowski, A.; Sauter, J.; Preeshagul, I.; Gillett, S.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Disease-related biomarkers are associated with extended progression free survival after treatment with NEO-PV-01 in combination with anti-PD1 in patients with metastatic cancers
    Meeting Abstract

    Ott, P.; Govindan, R.; Naing, A.; Friedlander, T.; Margolin, K.; Lin, J.; Bhardwaj, N.; Hellmann, M.; Awad, M.; Wanamaker, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis
    Meeting Abstract

    Peters, S.; Ramalingam, S. S.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; Sakai, H.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M. D.; Gubens, M. A.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Journal Article

    Hastings, K.; Yu, H. A.; Wei, W.; Sanchez-Vega, F.; DeVeaux, M.; Choi, J.; Rizvi, H.; Lisberg, A.; Truini, A.; Lydon, C. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Journal Article

    Aguilar, E. J.; Ricciuti, B.; Gainor, J. F.; Kehl, K. L.; Kravets, S.; Dahlberg, S.; Nishino, M.; Sholl, L. M.; Adeni, A.; Subegdjo, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001
    Meeting Abstract

    Garon, E. B.; Hellmann, M. D.; Costa, E. C.; Leighl, N. B.; Ahn, M. J.; Eder, J. P.; Balmanoukian, A. S.; Aggarwal, C.; Horn, L.; Patnaik, A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save